Marcus Klee

Marcus Klee

Marcus Klee

Managing Partner

Contacts

613-903-5100
613-558-7812
mklee@aitkenklee.com

Marcus represents clients in complex intellectual property litigation matters involving pharmaceuticals, medical devices, webcasting, finance, environmental remediation, aviation, and infrastructure. He is ranked in Lexpert; Chambers Global; Benchmark Canada; MIP; and the IAM Patent 1000. He was counsel on the “Milestone Case 2013” awarded by Managing Intellectual Property. He represented Gore in an exceptionally complex patent infringement and validity case involving artificial arteries.

Marcus has appeared before the Supreme Court of Canada, the Federal Court of Appeal, the Court of Appeal for Ontario, the Federal Court of Canada, the Ontario Divisional Court, the Ontario Superior Court of Justice, the Copyright Board of Canada, administrative bodies and arbitration tribunals.

Marcus received his Ph.D. from Queen’s University, and his law degree from Osgoode Hall. He was the recipient of numerous scholarships and academic awards. Dr. Klee was called to the Ontario bar in 2002 after clerking for multiple Justices at the Court of Appeal for Ontario.

Notable Matters

  • Representing Pharmascience Inc. as the Plaintiff in an action for s.8 damages for the drug abiraterone (T-732-22)
  • Representing Pharmascience Inc. as the Plaintiff in an action for s.8 damages for the drug fampridine (T-400-22)
  • Successfully represented Pharmascience Inc. and Laboratoire Riva Inc, including on appeal, in a summary trial before the Federal Court resulting in the dismissal of Eli Lilly’s claim of patent infringement in a case involving CIALIS (tadalafil) (2022 FC 1398; 2024 FCA 72)
  • Successfully represented Pharmascience Inc. in a summary trial before the Federal Court, and Federal Court of Appeal, which resulted in the dismissal of Pfizer’s claims of patent infringement in a damages case involving pregabalin (2019 FC 1271; 2020 FCA 55; [2020] S.C.C.A. No. 145, leave to appeal to SCC dismissed)
  • Represented Pharmascience Inc. in an action under the PM(NOC) Regulations for the drug efinaconazole (T-2251-22)
  • Successfully represented Pharmascience Inc. at trial and on appeal under the PM(NOC) Regulations regarding the multiple sclerosis drug fampridine (2020 FC 621; 2022 FCA 143)
  • Successfully represented Pharmascience Inc. and Les Laboratoire Riva in an action for patent infringement for tadalafil (2020 FC 816)
  • Represented Pharmascience Inc. in a trial involving the drug paliperidone palmitate (2022 FC 1218)
  • Represented Paid Search Engine Tools in a patent infringement action against Google (2020 FC 992; aff’d 2021 FCA 63 and 2021 FC 1435)
  • Successfully represented PCCI in an international fraud case and obtained a Mareva order and Anton Piller injunctions against multiple defendants resident in Canada (2019 ONSC 1142).
  • Successfully represented Teva Canada Limited in its claim for damages  and secured a finding of invalidity for two patents on grounds of obviousness, and secured a finding that a third patent was not infringed, for the drug bortezomib (2018 FC 754, 2019 FCA 273),
  • Successfully represented Teva Canada Limited in securing a s.8 damages award of $105 million (Teva Canada Ltd v Pfizer Canada Inc 2017 FC 526 Zinn J. on remand from 2016 FCA 161 var’g 2014 FC 248 and reasons re: pre-judgment interest 2014 FC 634.)
  • Successfully represented Teva Canada Limited before the Supreme Court of Canada in reversing two lower court decisions and defeating Pfizer’s patent for Viagra® (Teva Canada Ltd. v. Pfizer Canada Inc., 2012 SCC 60)
  • Successfully argued on behalf of the Association of Canadian Community Colleges and the Association of Universities and Colleges of Canada before the Supreme Court of Canada in an appeal involving fair dealing under the Copyright Act (Alberta (Education) v. Canadian Copyright Licensing Agency (Access Copyright), 2012 SCC 37)
  • Successfully represented L. Gore & Associates Inc. in a patent infringement and validity case involving artificial arteries.
  • Represented Re:Sound before the Supreme Court of Canada on a significant issue of statutory interpretation (Re:Sound v. Motion Picture Theatre Associations of Canada, 2012 SCC 38)
  • Successfully represented Teva Canada Limited in defeating a patent covering the schizophrenia drug SEROQUEL XR and securing market access (AstraZeneca Canada Inc. v. Teva Canada Limited, 2013 FC 245)
  • Successfully represented Suncor Energy in a patent infringement and validity suit involving environmental remediation technology for the oil sands (T- 1749-11)
  • Successfully represented Ratiopharm Inc. at trial and appeal in securing a declaration that a patent covering the blockbuster hypertension drug Norvasc® was invalid (Ratiopharm Inc. v. Pfizer Ltd. 2009 FC 711, affirmed 2010 FCA 204)
  • Representing Global Traffic Technologies, LLC in a patent infringement action involving priority traffic signal controls for emergency responders  (Global Traffic Technologies, LLC v. Emtrac Systems, Inc., T-736-11)
  • Successfully represented Ratiopharm Inc. in defeating a patent covering the pulmonary hypertension drug REVATIO and securing market access (Pfizer Canada Inc. v. Ratiopharm Inc.2010 FC 612).
  • Successfully represented Bombardier Aerospace in a patent infringement and validity action involving potable water systems for aircraft (International Water-Guard Industries Inc. v. Bombardier, T-1064-06)
  • Successfully represented Ratiopharm Inc. before the Federal Court of Appeal in securing market access for a generic version of the blockbuster drug EFFEXOR XR2  (Wyeth Canada v. ratiopharm Inc. 2007 FCA 264)
  • Represented Re:Sound before the Copyright Board of Canada in tariff setting proceedings.
  • Represented Novopharm Ltd.in a patent infringement and validity action involving the drug Levaquin® (Janssen-Ortho Inc. v. Novopharm Ltd. 2006 FC 1234, affirmed 2007 FCA 217)
  • Counsel to Mylan Pharmaceuticals ULC in several applications under the NOC Regulations involving patents covering the drugs Aricept®, Pantoloc®, and Nexium® (Pfizer Canada Inc. v. Mylan Pharmaceuticals ULC, 2011 FC 547; Lundbeck Canada Inc. v. Canada2010 FCA 320, aff’g 2009 FC 146; Nycomed GmbH v. Canada(2008) 64 C.P.R. (4th) 388 (F.C.)
  • Successfully represented Abbott Laboratories before the Federal Court, and the Federal Court of Appeal, in over 10 separate proceedings against generic drug manufactures involving patents for the drug Biaxin®.
  • Represented Neopost Canada Ltd. in successfully resisting the execution of an Anton Piller order and preventing the issuance of an interlocutory injunction in a trade secrets case (Neopost Canada Ltd. v. 566812 Ontario Ltd.(2003) 125 A.C.W.S. (3d) 404 (Ont. S.C.))
  • Stanley v. Ontario (Health Professions Appeal and Review Board)(2003) 5 Admin. L.R. (4th) 112 (Ont. Div Crt)
  • R v. Stucky (2005) 206 C.C.C. (3d) 140 (Ont S.C.)
  • Ontario Council of Hospitals Unions v. Ontario(2003) 125 A.C.W.S. (3d) 694; (Ont. Div Crt)
  • Stucky v. Canada (Attorney General) [2004] F.C.J. No. 2155 (F.C.T.D.)

Industry Recognition

  • Lexpert: Repeatedly Recommended (2023, 2022, 2021, 2019, 2018, 2017, 2016, 2015)
  • Chambers Global: The World’s Leading Lawyers for Business: Intellectual Property Litigation (2023, 2022, 2021, 2019, 2018, 2017, 2016, 2015, 2014, 2013, 2012, 2011, 2010)
  • Benchmark Canada: The Guide to Canada’s Leading Litigation Firms and Attorneys (2023, 2022, 2021, 2019, 2018, 2017, 2016, 2015, 2014, 2013, 2012) Litigation Star (for Intellectual Property)
  • IAM Patent 1000– ranked as one of the world’s leading patent practitioners, (2023, 2022, 2021, 2019, 2018, 2017, 2016, 2015, 2014, 2013, 2012)
  • Managing Intellectual Property: IP Star (2023, 2022, 2021, 2019, 2018, 2017, 2016, 2015, 2014, 2013, 2012)

Publications

  • “Chapter 4, Utility”,  Cameron ed., Canadian Patent Law Benchbook, Third Edition (Carswell 2019)
  • “Chapter 1: Patent Litigation “ in Paul Lomic ed., Intellectual Property Litigation: Forms and Precedents(LexisNexis Canada 2016).
  • “Chapter 4, Utility”,  Cameron ed., Canadian Patent Law Benchbook, Second Edition (Carswell 2014”
  • “Chapter 4, Utility”,  Cameron ed., Canadian Patent Law Benchbook, First Edition (Carswell 2012)
  • “Trade-marks: Infringement and Depreciation of Goodwill” in Donald M. Cameron, ed., Canadian Trade-Mark Law Benchbook, (Carswell 2012).
  • Utility, Intellectual Property Law Primer (Donald M. Cameron, ed.,) LSUC 2010, 2007).
  • “Copyright”, in R. Dimock, ed. Intellectual Property Disputes: Resolutions and Remedies(Carswell, 2002+).
  • Intellectual Property – The Year in Review, Update on Copyright, Law Society of Upper Canada, 2011, and 2012.
  • Canadian Copyright, Design, and Related Legislation and Jurisprudence: 2011, CIPR, Vol 28, No. 1 June 2012

Professional Affiliations

  • Law Society of Ontario
  • Canadian Bar Association
  • Advocates Society
  • Intellectual Property Institute of Canada